PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for cardiopulmonary diseases. Co.'s primary product candidate, bentracimab, is a reversal agent for the antiplatelet drug ticagrelor. Co. is developing its preclinical product candidate, PB6440, is an aldosterone synthase inhibitor being developed for treatment-resistant hypertension. Co.'s preclinical programs include: Glucagon-like peptide-2, which stimulates growth of intestinal villi, increasing their ability to absorb nutrients and C-type natriuretic peptide, which is a regulator of bone growth and can rescue defects in fibroblast growth factor 3. We show 18 historical shares outstanding datapoints in our PHAS shares outstanding history coverage, used to compute PHAS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PHAS market cap history over the course of time is important for investors
interested in comparing PHAS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PHAS versus a peer is one thing; comparing
PHAS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PHAS can fluctuate over the course of history.
With this page we aim to empower investors researching PHAS by allowing them to research the PHAS market cap history. |
Free PHAS Email Alerts:
Video: The Importance of Market Cap
